KPIs & Operating Metrics(New)

Balance Sheet

Cash Flow Statement

Acquisitions Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Dividends Paid - Common Dividends Paid - Common Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Repurchased Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Biolife Solutions (BLFS) Amortization of Deferred Charges (2011 - 2023)

Biolife Solutions (BLFS) reported Amortization of Deferred Charges of $13000.0 for Q1 2023, down 27.78% on a QoQ basis from $18000.0 in Q4 2022.

Biolife Solutions (BLFS) has 8 years of Amortization of Deferred Charges data on file, last reported at $13000.0 in Q1 2023.

Quarterly Amortization of Deferred Charges changed N/A year-over-year to $13000.0 in Q1 2023, while the trailing twelve-month figure through Dec 2023 was $13000.0 (down 27.78% YoY) and the FY2023 annual result came in at $13000.0, down 27.78% from the prior year.
Amortization of Deferred Charges slipped to $13000.0 in Q1 2023 per BLFS's latest filing, from $18000.0 in the prior quarter.
Across five years, Amortization of Deferred Charges topped out at $18000.0 in Q4 2022 and bottomed at $13000.0 in Q1 2023.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Intuitive Surgical	156.17 Bn	151.78 Bn	1.83 Bn
2	Becton Dickinson	41.51 Bn	40.49 Bn	2.15 Bn
3	Resmed	30.43 Bn	28.77 Bn	890.98 Mn
4	West Pharmaceutical Services	22.78 Bn	22.26 Bn	296.40 Mn
5	Solventum	13.39 Bn	13.39 Bn	1.10 Bn
6	Cooper Companies	12.33 Bn	12.20 Bn	695.20 Mn
7	Align Technology	11.65 Bn	10.59 Bn	736.59 Mn
8	Baxter International	9.81 Bn	7.77 Bn	891.00 Mn
9	Aptargroup	7.39 Bn	7.19 Bn	351.91 Mn
10	Biolife Solutions	1.20 Bn	1.12 Bn	17.50 Mn

Historic Data

Download Data 🔒

Date	Value
Mar 31, 2023	13,000.00
Mar 31, 2023	13,000.00
Dec 31, 2022	18,000.00
Dec 31, 2022	18,000.00
Dec 31, 2016	181,984.00
Dec 31, 2016	181,984.00
Jun 30, 2016	86,736.00
Jun 30, 2016	86,736.00
Mar 31, 2016	-31,749.00
Mar 31, 2016	-31,749.00
Dec 31, 2015	31,750.00
Dec 31, 2015	31,750.00
Mar 31, 2015	-31,750.00
Mar 31, 2015	-31,750.00
Mar 31, 2014	13,022.00
Mar 31, 2014	13,022.00
Dec 31, 2013	-31,674.00
Dec 31, 2013	-31,674.00
Sep 30, 2013	14,263.00
Sep 30, 2013	14,263.00
Jun 30, 2013	14,107.00
Jun 30, 2013	14,107.00
Mar 31, 2013	-13,333.00
Mar 31, 2013	-13,333.00
Dec 31, 2012	-687,543.00
Dec 31, 2012	-687,543.00
Sep 30, 2012	18,397.00
Sep 30, 2012	18,397.00
Jun 30, 2012	14,701.00
Jun 30, 2012	14,701.00
Mar 31, 2012	27,045.00
Mar 31, 2012	27,045.00
Dec 31, 2011	121,464.00
Dec 31, 2011	121,464.00
Sep 30, 2011	-20,307.00
Sep 30, 2011	-20,307.00
Jun 30, 2011	11,430.00
Jun 30, 2011	11,430.00
Mar 31, 2011	15,324.00
Mar 31, 2011	15,324.00